GLP-1 Bridge formCorrect path
Zepbound 2.5mg
Obesity plus a qualifying comorbidity. Routes to the CMS central processor at a $50 copay.
Latent · A working paper · Medicare's GLP-1 Bridge
Millions now qualify for the GLP-1 Bridge.
How we're helping our partners meet the demand.
Medicare's largest medication-access expansion in a decade is here. The health systems we partner with saw it coming, so we prepared with them. Here is that work, in order: the message they brought us, what we found when we looked into the problem, what we built for the volume and the routing, then the autonomous workflows we are building next.
Scroll to begin.
01 · They came to us
Our partners came to us to get ready for the Bridge.
In one week, several of our partners came to us for help. We build Latent with these teams: an enterprise pharmacy intelligence platform built to help patients on their journey to health. They asked the same thing: help us get ready for the Bridge. Medicare was opening GLP-1 coverage to a large new group of patients, and our partners, many of them leading health systems, saw the rise in newly eligible patients coming, along with the prior-authorization work behind it. They could not hire fast enough to meet it. That is why we wrote this paper, and it is where we started, by looking at the problem with them.
Drawn from inbound requests across the Latent network in the weeks before launch.
02 · What we found
We were already helping, but the Bridge brings new levels of strain.
We had already been handling part of the medication-access work for these teams, including the prior approvals that stand between a patient and their medication, so we knew their pharmacies before this started. When they came to us about the Bridge, we looked closely at what was still pulling on them, and what we found was straightforward. The strain comes from a few forces that have been building for years: technicians who left and were not replaced, shifts no one could cover, and prescriptions that waited. None of them is easing on its own. The Bridge does not add a new kind of problem; it raises the volume on these standing ones, and that is where the new strain comes from. Open each to see what the team is up against.
These forces are structural, so more volume only presses harder on them. Here is the gap that was opening, and where Latent had already started to close it.
Index (2020 = 100). Illustrative, grounded in IQVIA and Latent network data.
We already helped change this curve.On its own, the team stays flat. With Latent the same people reach far more, with no new hires, so the gap that was opening is already closing. The demand the Bridge brings is what we take on next, together.
03 · The volume
Millions who were not eligible now qualify.
Then we looked at how big it could get. Nearly 14 million Medicare beneficiaries are diagnosed with obesity ASPE, 2024, and while the share who qualify for the Bridge is narrower, it is large enough to reshape the workload. As of July 1, 2026, Medicare covers GLP-1 medicines for those who meet the Bridge's clinical criteria, usually an obesity diagnosis alongside a qualifying comorbidity. For two decades, a 2003 statute locked these patients out, written when the country still treated obesity as cosmetic. The cash price they faced was more than $1,000 a month. Under the Bridge it is $50.
Cash price, before
$1,000+/mo
Under the Bridge
$50/mo
GLP-1 claims in Medicare Part D had already risen nearly fivefold, from 4.8 million in 2019 to 21.8 million in 2024, before this coverage ever began. KFF, 2024
04 · The hard part
Routing one case correctly is harder than it looks, and the Bridge brings millions of them.
Volume was only the first problem our partners named. The second is harder, and it hides inside every single case. The same medicine, the same patient, can go two ways. If a non-obesity indication qualifies, it runs on the standard Medicare form. If the basis is obesity plus a comorbidity, it must go on a separate Bridge form. The answer is not printed on either form. It is in the chart, before any PA exists. Today that read falls to a pharmacist, case by case. Get it wrong and no one knows until the rejection comes back: the original submission has already spent its review window, the resubmission waits again, and Bridge volume stretches every queue behind it. Latent's agents reason over the patient chart to flag whether a case qualifies for the Bridge, and with our Early Adopter Partners we're extending that so agents carry the authorization through.
Indication on the chart
Standard Medicare formCorrect path
Zepbound 2.5mg
Type 2 diabetes, sleep apnea, or another indication. Routes to the patient's Part D plan.
The same drug sits on both forms. Which one is correct depends entirely on what the chart says, and only a chart read tells you which.
Routed correctly the first time
Care proceeds, no added wait
Wrong form, then resubmission
~21 days lost
071421days of delayed care
The wrong form is not caught until it is rejected. The original submission burns its full review window (~14 days) before anyone knows, and the resubmission waits again (~7 days), on top of the delay Bridge volume adds to every queue. The hatched segment is the resubmission. Review-window estimates reflect standard Medicare PA timelines; Bridge-specific data is not yet available.
05 · What we built
Latent reads the chart and routes the case.
Latent built a system that reads the chart, finds the obesity diagnosis and the qualifying comorbidity, rules out the cardiovascular overlap that would route the case to Part D instead, and recommends the right path with its reasoning attached. A read that used to wait on a pharmacist now takes seconds.
Run it yourself. This is a faithful, synthetic re-creation of the check, on a synthetic patient. Change M. Torres's chart and watch the route change.
Checking Zepbound 2.5mg for M. Torres
Assistive today, by design.
Latent routes the case and shows its reasoning; the pharmacist makes the final call. For July 1, that is the right balance of trust, and it is only the first step. Together with health systems, we are already building toward agents that take on the whole task, so fewer cases ever have to reach a person.
06 · Already scaling
Our partners are already serving more patients with the same teams.
This is already running today. Most of our partners run Latent, our enterprise pharmacy intelligence platform, across their pharmacy. The check does not lower the volume, which is real and already here. It makes each case less work, so the same team can serve more of the patients behind it. Across our partners, here is what that adds up to.
The same team handles twice the work.
2×
patient capacity for clinicians on the platform.
Teams scale without adding people.
60+
health systems live, half of the top 20 in the U.S.
More patients get their medication faster.
2M+
patients a year accessing medications faster.
Fewer cases come back rejected.
30%+
reduction in medication denials across partners.
"Once Latent took that body of work off their plates, our team's energy skyrocketed. With a reinvigorated team, we've been able to focus on what matters most: delivering exceptional care to more patients in need."
Network figures reflect Latent's medication-access engine across prior authorization and specialty work, not a single program. Partners named with permission: Yale New Haven, Ochsner, MetroHealth, UCI, Vanderbilt, Mount Sinai, Henry Ford, UCSF, UCLA, St. Luke's.
07 · What's next
Next: autonomous agents that do the work.
The Bridge check is only the beginning. Together with health systems and on their terms, we are building toward agents that can take on the most time-consuming and complex administrative work, when a system wants it and how they want it, sometimes a single step and sometimes the whole task, so more of it is handled before it reaches a person.
We're building toward taking on even more of the workload.
Same team, no new hires. As Latent does more of the work, by hand, then assisted, then autonomous, the team's capacity rises to meet the demand with you.
The same team, more capacity at each stage
By hand, the gap is wide.The team stays the same size while demand keeps rising. This is where most pharmacies start.
Autonomous PA agent · in development
2,840 cleared
When you ask pharmacists why they do this work, almost none of them say the forms. They say the patients. Every minute this saves is a minute a clinician can spend with a patient. That is the point of doing this work: to reach more people, so no one is left waiting.
When Latent takes on the paperwork, the team gets that time back to spend with patients.
Let's talk about how Latent can help your pharmacy.
The Bridge raises the volume for everyone. Get in touch and we'll walk you through how Latent handles the medication-access work alongside your team, on your terms.
Get in touch with our teamThis paper was written by Clay Coleman with a clinician's read, and built with the same system it describes: a working draft, routed, reviewed, and improved with the same tools. We held every number to its source. Where the workforce evidence was still firming up, we said so. Every patient here, M. Torres included, is synthetic, used only to illustrate the work. No real patient data appears.
Frequently asked
Common questions about the GLP-1 Bridge
What is Medicare's GLP-1 Bridge?
As of July 1, 2026, Medicare covers GLP-1 medicines for those who meet the Bridge's clinical criteria, usually an obesity diagnosis alongside a qualifying comorbidity. For two decades a 2003 statute locked these patients out. The cash price they faced was more than $1,000 a month. Under the Bridge it is $50.
Why is the Bridge hard for pharmacy teams?
The same medicine, for the same patient, can route two ways, and the answer is not printed on either form. If the basis is obesity plus a comorbidity, it must go on the separate Bridge form, which routes to the CMS central processor at a $50 copay. If a non-obesity indication qualifies, such as type 2 diabetes or sleep apnea, it routes to the patient's Part D plan. Only a chart read tells you which path is correct.
How does Latent help with Bridge cases?
Latent reads the chart, finds the obesity diagnosis and the qualifying comorbidity, rules out the cardiovascular overlap that would route the case to Part D instead, and recommends the right path with its reasoning attached. A read that used to wait on a pharmacist now takes seconds.
Does Latent make the final decision?
No. Latent is assistive today by design. It routes the case and shows its reasoning, and the pharmacist makes the final call.
What results are Latent partners already seeing?
Across Latent's partners, clinicians on the platform handle about twice the patient capacity with the same team, more than 60 health systems are live including half of the top 20 in the U.S., more than 2 million patients a year are accessing medications faster, and medication denials are down more than 30 percent.